The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy
Can J Cardiol. 2011 Jul-Aug;27(4):415-433.e1-2.
doi: 10.1016/j.cjca.2011.03.015.
[Article in
English,
French]
Authors
Doreen M Rabi
1
, Stella S Daskalopoulou, Raj S Padwal, Nadia A Khan, Steven A Grover, Daniel G Hackam, Martin G Myers, Donald W McKay, Robert R Quinn, Brenda R Hemmelgarn, Lyne Cloutier, Peter Bolli, Michael D Hill, Thomas Wilson, Brian Penner, Ellen Burgess, Maxime Lamarre-Cliché, Donna McLean, Ernesto L Schiffrin, George Honos, Karen Mann, Guy Tremblay, Alain Milot, Arun Chockalingam, Simon W Rabkin, Martin Dawes, Rhian M Touyz, Kevin D Burns, Marcel Ruzicka, Norman R C Campbell, Michel Vallée, G V Ramesh Prasad, Marcel Lebel, Tavis S Campbell, M Patrice Lindsay, Robert J Herman, Pierre Larochelle, Ross D Feldman, J Malcolm O Arnold, Gordon W Moe, Jonathan G Howlett, Luc Trudeau, Simon L Bacon, Robert J Petrella, Richard Lewanczuk, James A Stone, Denis Drouin, Jean-Martin Boulanger, Mukul Sharma, Pavel Hamet, George Fodor, George K Dresser, S George Carruthers, George Pylypchuk, Richard E Gilbert, Lawrence A Leiter, Charlotte Jones, Richard I Ogilvie, Vincent Woo, Philip A McFarlane, Robert A Hegele, Luc Poirier, Sheldon W Tobe; Canadian Hypertension Education Program
Affiliation
- 1 Department of Medicine, University of Calgary, Calgary, Alberta, Canada. doreen.rabi@albertahealthservices.ca
Abstract
We updated the evidence-based recommendations for the diagnosis, assessment, prevention, and treatment of hypertension in adults for 2011. The major guideline changes this year are: (1) a recommendation was made for using comparative risk analogies when communicating a patient's cardiovascular risk; (2) diagnostic testing issues for renal artery stenosis were discussed; (3) recommendations were added for the management of hypertension during the acute phase of stroke; (4) people with hypertension and diabetes are now considered high risk for cardiovascular events if they have elevated urinary albumin excretion, overt kidney disease, cardiovascular disease, or the presence of other cardiovascular risk factors; (5) the combination of an angiotensin-converting enzyme (ACE) inhibitor and a dihydropyridine calcium channel blocker (CCB) is preferred over the combination of an ACE inhibitor and a thiazide diuretic in persons with diabetes and hypertension; and (6) a recommendation was made to coordinate with pharmacists to improve antihypertensive medication adherence. We also discussed the recent analyses that examined the association between angiotensin II receptor blockers (ARBs) and cancer.
Copyright © 2011 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antihypertensive Agents / therapeutic use
-
Blood Pressure Determination
-
Canada
-
Health Education
-
Humans
-
Hypertension / diagnosis*
-
Hypertension / drug therapy*
-
Risk Assessment